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Abstract
Among the numerous infectious diseases, malaria remains a major health chal-
lenge. Despite the various approaches adopted for the vector control and availability 
of antimalarial drugs, the success of malaria eradication is dampened by the spread 
of drug and insecticide resistance, unavailability of proper diagnostic treatment 
and successful vaccine. Among the various approaches, vaccination with the aim 
of developing protective immunity is the most suited, safe and reliable approach 
for the entire mankind. Numerous approaches are in use for vaccine development; 
however, they suffer from the drawbacks that immunity developed is short lived 
and are both species- and stage-specific. Of late, radiation sterilization has drawn 
the attention in the vaccine development due to its advantages over the conventional 
methods, and successful clinical trials of irradiated vaccines against the patho-
gens and tumor. Recently, a novel approach of genetically attenuated sporozoites 
(PfRAS, PfSPZ, PFSPZ-GA1 sporozoites vaccines) has shown promising results by 
generating protective immunity against the homologous and heterogenous infec-
tion in the clinical trials. Radiation techniques have also been beneficial in control-
ling the insects by sterility technique. In this chapter, we have recapitulated the role 
of radiation biology in the malaria vaccine development with its current status and 
future challenges associated with the development of radiation attenuated parasite 
vaccine.
Keywords: malaria, infectious disease, vaccine, radiation technology, immunity, 
genetically attenuated sporozoites
1. Introduction: basic malaria biology
Malaria, an ancient disease has been found recorded in several historical docu-
ments and the word malaria comes from the Italian mal’aria meaning spoiled air [1]. 
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It is a vector born disease caused by the parasite, belonging to genus Plasmodium 
and out of five different species, the burden of malaria leads by Plasmodium falci-
parum followed by Plasmodium vivax in humans [2]. 219 million cases of malaria 
were reported in 2017 with the death toll of 4,35,000 and the latest world malaria 
report suggest the stalled in the progression of the reduction in malaria elimination 
across the globe [3].
Almost half of the world population is at the risk of malaria, with more than 85% 
cases in sub-Saharan Africa followed by South-East Asia, West Pacific and others [3]. 
The population groups are at higher risk of malaria, and developing fatal severity 
include infants, children under 5 years of age, pregnant women, immunocompro-
mised patients, non-immune migrants, mobile populations and travelers [4, 5]. In 
areas where malaria transmission rate is high, among these, children under 5 years 
are particularly receptive to infection, Illness, and death; more than 2/3 (70%) of all 
malaria deaths occur in this age group [4]. The number of under age of 5 years for 
malaria deaths has declined from 4,40,000 in 2010 to 2,85,000 in 2016, nevertheless, 
it remains as a leading reason for the death under 5 years children, taking the life of a 
child every 2 minutes [3].
1.1 Malaria life cycle
Plasmodium spp., a Causative parasite for malaria exhibits a complex life cycle 
that switches between Anopheles mosquitoes (vector), and invertebrate hosts that 
form unique zoite formation to evade different cell types at specific stages [6, 7]. 
It comprises of three different types, two of these (asexual stage) in vertebrate 
which are exo-erythrocytic cycle (liver/asymptomatic stage) and erythrocytic cycle 
(blood/symptomatic stage). And the third phase (sexual stage) is in the mosquito 
that is sporogenic cycle (infective stage) [7].
During the probing for the blood meal using its proboscis on the host, the 
infected female mosquito injects sporozoites (SPZs) within its saliva into dermis of 
uninfected human [8, 9] which contains vasodilators and anticoagulants that facili-
tate the ingestion of blood [10]. Most of the parasites reside in the skin between 
1 and 6 hours [7, 8]. Many fail to migrate to the lymph nodes (LNs) and approxi-
mately 20% of them migrate directly into the skin-draining LNs through the lymph 
[11, 12]. It triggers the induction or modulation of the host immune system followed 
by an antiparasitic immune response [13, 14]. On the other hand, a small propor-
tion of SPZs randomly transverse to the nearest blood vessel [12]. After crossing 
the endothelial barrier of the skin, the SPZs enter to the circulation and reached to 
the liver which is critical for the infection cycle as the development of merozoites 
occurs [15–18].
The traversal activity of SPZs through different host cells and molecular 
events that underpin the transformation of SPZs into merozoites via erythro-
cyte invasion involves the expression of thousands of proteins [7]. These SPZs 
migrate via blood flow to the liver retained by hepatic stellate cells (HSC) and 
glide, further using the Kupffer cells as a shield, traverse the liver sinusoidal 
endothelial cells (LESC) barrier in a sinusoids [8]. It has been moving in sev-
eral hepatocytes through the space of Disse by the thrombospondin related 
anonymous protein (TRAP) and circumsporozoite protein (CSP) interactions 
before actually infecting one of them to form a parasitophorous vacuole, that 
aids in protecting from the host’s immune system and provides nutrients for 
the SPZs to replicate and differentiate into merozoites [8, 10]. The healthy or 
successful sporozoites release up to 10,000 to more than 30 to 40,000 merozo-
ites per hepatocyte into the bloodstream within parasite-filled vesicles called 
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merosomes through a process of budding which use the host-cell membrane to 
escape the host immune system (Figure 1) [19].
The merozoites release in the hepatic circulation that invades erythrocytes in 
a short duration via dynamic and multi-step process that includes pre-invasion, 
active invasion, and echinocytosis [21] through the involvement of proteins 
named merozoite surface protein (MSP) [7]. The blood stage is symptomatic stage 
that develops once the erythrocytic cycle produces a parasitemia above a certain 
threshold approximately 50–100 parasites/μL (microscopy). The merozoites 
released into the blood reinvade the new red blood cells (RBCs) and continue to 
replicate or in some instance, they differentiate into male and female gametocytes 
[22, 23]. Mature gametocytes travel throughout the body and deposited mainly 
in skin capillaries from which they are taken up by the mosquito for the next 
blood meal. Once they reach to the mosquito gut, male gametocyte produces eight 
microgametes with three rounds of mitosis, meanwhile female gametocyte mature 
in macrogametes in the gut of the mosquito [24]. The fusion of the male and female 
gametocyte forms a diploid zygote that elongates into an ookinete; which exits 
the epithelium through the lumen of the gut as an oocyst and undergoes cycles of 
replication and forms sporozoites. It moves from the abdomen and resides into the 
Figure 1. 
The basic malaria life cycle of Plasmodium falciparum (adapted from [20] with permission).
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salivary gland followed by the next blood meal of mosquito during which it will 
inject the sporozoites to the healthy host [24].
1.2 The liver stage infection of malaria parasites: yet hold promises
The liver is the most important organ and known for its role in blood purifica-
tion, detoxification of chemicals and metabolizes of drugs, role in the immune 
system and homeostasis [25]. This unique architecture of liver favors the interaction 
between leukocytes and hepatic cells and intra-hepatic recruitment of T cells which 
recognize their cognate antigen within their vicinity [26]. Among the multi-stage 
life cycle, liver/exoerythrocytic stage of the malaria parasite is least known due to 
several reasons, however recent developments of humanized mice have revealed 
the importance of liver stage [2]. All the same, liver stage parasites in murine and 
humans evade the immune clearance despite the presence of antigen presenting 
cells (APCs) [8]. Cytotoxic T cell (CD 8+ T cell) requires to kill the intracellular 
parasite infected cell as they are intracellular organism reside in the hepatocytes. 
Therefore long lasting immunity, reduce/remove the parasitic load in asymptomatic 
exoerythrocytic stage and to prevent their liver to blood stage transitions are the 
main concern for any malarial parasitologist to develop and improve the vaccine 
strategies.
1.3 Current status of antimalarial therapy and standing of vaccine initiative
To prevent and eradicate malaria, prophylaxis that has no adverse effect and 
versatile for all is an urgent requirement. Till now various antimalarial therapy of 
drugs, insecticide-treated bed nets and different diagnostic tests [27] are in use, 
however the success of malaria infection halted by the insecticide [28, 29] and para-
site resistance [28, 30, 31]. This life-threatening condition needs the novel antima-
larial therapy that can control parasite at different stages of its life cycle (Figure 2).
Figure 2. 
Schematic diagram of intra-erythrocytic trophozoite showing targets of novel antimalarial drugs (red color 
indicates the drugs under the pipeline/clinical trials and green color for the drugs currently available) (adapted 
and modified from [32]).
5Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity…
DOI: http://dx.doi.org/10.5772/intechopen.85491
Nowadays, a novel approach of combinational drug therapies are in use such as 
Artemisinin based combinatorial therapy (ACT) and others though, the success 
rate is low or restricted to the area due to the diversity among the parasite [33]. 
Despite the availability of drugs from natural resources or synthetic compound, the 
parasite still surpasses and escape the host immune system as well as dampen the 
effect of the drugs [34]. Also, the recent finding has alarmingly shown that parasite 
has been gaining resistance against artemisinin and its derivatives [31, 35]. In this 
bleak condition, the malaria vaccine is urgent and indeed. Different approaches are 
in practice for the development of malaria vaccine based on immunogenic pep-
tides, usage of mosquito and/or parasite antigens, usage of adjutants, radiation or 
genetically modified sporozoites and so on [36]. Different experimental evidences 
shed the light on the importance of novel vaccine approaches (attenuated whole 
sporozoites) which strongly confirms the role of APCs resides in the liver capable 
to recruit CD 8+ T cells together with the cytokines (IFN-γ and TNF-α) required 
for the sterile protection [21, 37–43]. Despite the sterile immunity last longs for the 
6–9 months, a recent study confirmed the usage of the intermittent challenge of 
radiation attenuated sporozoites in mice stay long lasting up to 18 months and give 
rise to sterile immunity [44]. The approach of radiation for protective immunity has 
gained attention in the scientific community to eradicate the morbidity and mortal-
ity of malaria infection.
2. Radiation and its impact on health
Radiation is a form of energy which travels and transmits or emits from its 
source as a wave (ionization radiation) or in the form of electron particles (non-
ionizing radiation) [45]. The broad range of electromagnetic spectrum consists of 
harmless radio and microwaves, sunlight includes longer (infrared) and shorter 
(ultraviolet) wavelength and finally the higher energy specific wavelength of X-rays 
and gamma rays which exist the electrons from the atoms through the ionization 
process [45, 46]. During the process of radioactive decay there are mainly three 
types of ionizing radiation emitted; alpha, beta and gamma rays. Other than this, 
X-rays can be occurred naturally or produced by machines [47]. The major dif-
ference between this ionizing radiation (X-rays and gamma rays) is the photon’s 
energy of individual rather than the energy of the total dose of the radiation 
alongside their source of origin [48].
As the entire world is in the vicinity of the radioactive environment, we all, 
more or less, are exposed to a certain level of background radiation [49]. It has been 
reported that more than 80% of human-radiation doses are uncontrolled which are 
mainly consist of the natural sources, terrestrial and exposure through inhalation or 
intake of the radiation (mainly through medication) [50].
There are more than 60 natural radionuclides are found in the environment 
and no place on the earth is without spontaneous radiation activity. It is mainly 
observed in the soils and rocks (uranium and thorium decay), in water sources 
such as naturally occurred lacks, rivers and oceans and Human-made buildings 
and homes [51]. Also, the effect of gamma radiation on natural radioactivity and 
their associated exposures mainly depends upon the geological and geographical 
location together with their appearance at different levels in the soil of the respec-
tive the region [50]. Overall, we received an average dose of 2.4 mSv/year (mSv 
stands for millisieverts, one-thousandth part of a sievert, an SI unit and currently 
used in the radiation protection standards) from the background radiation which 
may vary from 1 to 10 mSv/year and rely on the location of the region; however it 
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can exceed above the 50 mSv/year. Therefore, if an average of 2 mSv/year of the 
radiation dose exposed to an individual, the person at the age of 80 years will be 
accumulated almost 160 mSv radiation originated from the natural sources [50].
2.1 Radiation biology
The term radiation biology came across into the picture during 1963 when 
Bergonie and Tribondeau assumed and stated that the immature, undifferentiated 
and continuously dividing cells are more prone towards the radiation with compare 
to the cells which are fully matured, differentiated and not actively participated in 
the cell division process [52]. Therefore, the radiosensitive cells such as stem cells, 
the stratum basal of the skin and stomach mucosa; continuously experiencing 
cell division (mitosis) and exhibits certain effects after the exposure towards the 
ionizing radiation resulting into the cell death or cell injury. Contradictory, the 
radioresistant cells such as neurons which never divides or do it very slowly show 
less inclined towards the cell injury or death after the radiation exposure [53]. The 
experiments carried out on fruit flies and mice have shown the effects of radiation 
as mutation was occurred however, it was notified that all the mutation were similar 
to the spontaneously generated one. Also, it was linked to the dose and exposure 
rate of the respective ionizing radiation [54].
2.1.1 Interaction between radiation and human cells
The interaction of human cells and radiation is just the likelihood and 
therefore, any permanent damage occurs to the tissues is not due to the facing 
off them each other during the cellular repair mechanism [53]. The processes of 
energy deposition have not any signature pattern (very rapid, 10−18 s) and the 
interaction takes place at the cellular level affect the organ as well as the entire 
system [45]. Alongside, there is no established cellular damage associated with 
the radiation, and heat, chemical or physical damage is also accounted for the 
same. The destruction occurs as a result of radiation towards the cells has the 
latent period followed by observable responses. The latent period remains for a 
prolonged time in case of low radiation whereas, it accounts for minutes to hours 
for the higher dose of radiation and the radiation biology entirely rely on these 
basic principles [53, 55].
The interaction of ionizing radiation with the cells, possibly occur through 
any of the two ways; direct interaction within the cells hit the macromolecules 
(proteins and DNA) resulting into the death of the cells or the mutation of the 
DNA. This mechanism can happen during the higher doses of the radiation as the 
cellular repair mechanism is tightly regulated [53]. Another one is the indirect 
pathway where the radiation energy is trapped inside the cellular compartment 
and interacts with the water rather than macromolecules followed by hydrolysis of 
water produced the free radicals inside the cells [53, 56]. This will lead to the loss 
of the important enzymes resulting in the cell death or the mutation. As the result 
of an interaction, there are mainly three types of cellular injury arises: (1) delayed 
division, (2) failure of the reproduction and (3) death during the interphase of the 
cell cycle [53].
The intensity of the damage occurs inside the cells rely upon various parameters 
including the types and its source, duration, doses, exposure and its energy [57]. 
The knowledge about the risk of the radiation has been studied, documented and 
referred well from the survivor of the atomic bombs at Hiroshima and Nagasaki in 
the Japan during the Second World War. Also, the additional inputs are given by the 
studies conducted on the radiation industry workers [45].
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2.2 Radiation therapy: application in medical research
It was during the 1895, when Wilhem Roentgen has invented the X-rays to see 
the things visibly inside the body without surgery. This historic discovery has 
transformed the medical field and currently, it has been widely used to diagnose the 
injuries and diseases [45]. At present, more than 50% of our exposure contributed 
to the medical sources lead by X-rays and CT scan. Nowadays, understanding 
the radiation risk and their effects at molecular, cellular and organ level is mainly 
Figure 3. 
Radiation therapy and their different consequences can be used for antitumor combination therapy for cancer 
therapeutics (adapted from [62] with permission).
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studied for the diseases. This will bridge the gap and guide the health physicist 
to determine the safety level of the radiation to use in the medical, industrial and 
scientific world for the betterment of the mankind [45, 49, 58].
Despite the hazardous effects of radiation on the cells, if the cell death mecha-
nism is instinct or properly targeted then it will be the achievement in the medical 
field for the cancer patients where it is using as radiation therapy [59]. It still remains 
as the preliminary cancer treatment and more than 50% of all the cancer patients 
received radiation therapy and stands for 40% of the curative treatment [60]. It is 
believed that it can evoke the tumor-specific immune response to destroy the tumor 
cells as well also travel to the site of the disease [61].
Recent research confirms the potential usage of radiation therapy in cancer 
therapeutics by converting tumor to favorable condition and makes them immuno-
stimulatory milieu [62]. Experiential data suggest that the combination of radio-
therapy alongside the immunotherapeutic agents can produce the synergistic effects 
(Figure 3) [61, 62]. From all the above-stated information, it has become clear that 
recent developments in radiation therapy [61, 63, 64] may have proven to be the 
most critical part in the successful development of cancer vaccine.
2.2.1 Radiation and vaccine development
Usage of chemical and physical methods to develop a stable and safe vaccine is 
the gold standard method through which the pathogen will be converting into the 
inactive form. Despite the successful application in various medical conditions 
to eradicate the disease or to develop the sterile immunity; the fast, reliable and 
rapidly generated vaccine is required [58]. Recently, radiation sterilization is been 
under the process for the vaccine development which surpasses the chemical or 
other types of contamination. Also, it destroys the nucleic acid of the respective 
pathogens through penetration without disturbing the cell surface antigens. It is 
been in under the clinical trials for the various types of cancers [65–67] however, 
due to the issues of safety and other regulatory affairs it is under development at 
industrial level [58]. On the other side, results of current clinical trials of using 
the various irritated vaccines for numerous pathogens and tumors has attracted 
the researcher and scientific world towards the preparation of various radiation-
based vaccine for various infected and non-infected diseases [61, 62, 64, 68]. The 
ongoing effective development of irradiated vaccines for malaria and influenza 
have exhibited the attainability of this approach, and have shown the promis-
ing results alongside the advantages of the radiation therapy by overcoming the 
limitation of existing facilities without using any sophisticated technological 
approach [69, 70].
3.  Role of radiation therapy in malaria vaccine: developments and 
challenges
Malaria vaccine development is an active research area with enormous chal-
lenges. An effective vaccine for P. falciparum is needed in malaria-endemic popula-
tions; however, none of the licensed malaria vaccines and candidates consistently 
produced long-lived protection [71, 72]. The malarial parasite undergoes continu-
ous morphological changes and displays antigenic variations during the entire 
life cycle in both the host [73]. As a result, parasite evades the protective immune 
responses of the host and long-term protective immunity is not observed in 
malaria-infected individuals [74, 75].
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Plasmodium falciparum has a multi-stage life cycle and a large 23 Mb genome 
expressing 5268 putative proteins. Many of these proteins exhibit allelic varia-
tion between species or antigenic polymorphism typically at sites recognized 
by antibody or T cell responses [76]. To date, only a handful of the nearly 5300 
potential target antigens expressed by P. falciparum, representing less than 0.3 
percent of the genome, have been pursued as vaccine targets [76, 77]. From the 
host perspective, malaria is a chronic infection and the Plasmodium parasite is 
capable of evading or modulating the host immune response. Based on the life 
cycle of the malaria parasite and the process of infection, malaria vaccines are 
divided into four potential target groups; interruption of human to mosquito 
transmission (parasite sexual and mosquito stages), inhibition of clinical conse-
quences (asexual blood stage), prevention of mosquito to human transmission, 
and pre-erythrocytic infections (sporozoite [SPZ]/liver stages) [78]. As per the 
recent advancement in the malaria vaccine development mainly three types of 
vaccine candidate targeting different stages of malaria parasite have been inten-
sively investigated named as pre-erythrocytic vaccines, blood-stage vaccines and 
transmission-blocking vaccines [79, 80].
3.1 Pre-erythrocytic vaccines
The pre-erythrocytic stage does not cause clinical disease, and there is no 
convincing evidence for naturally acquired protective immunity to this stage in 
individuals living in malaria-endemic areas [81]. Thus, this stage would appear 
to be an unattractive vaccine target. Nonetheless, the most advanced vaccine in 
development is a protein expressed at this stage that covers the parasite surface, the 
circumsporozoite protein (CSP). One of the most advanced anti-malaria vaccines 
at a clinical level is the RTS,S/AS01, a subunit vaccine consisting of the P. falci-
parum CSP fused with the hepatitis B surface antigen (HBsAg) [82–85]. Although 
this vaccine did not appear to elicit a CD8+ T cell response, CSP-HBsAg induced a 
specific CD4+ T cell response targeting the whole SPZs [86, 87]. The mechanism 
by which RTS,S confers protection against the blood-stage disease remains poorly 
understood. It seems that RTS,S induces protection against clinical malaria by 
temporarily reducing the number of merozoites emerging from the liver [69]. This 
may allow prolonged exposure to subclinical levels of asexual blood-stage para-
sites, therefore boosting the naturally acquired blood-stage immunity.
3.2 Blood stage vaccines
Blood-stage vaccines work on the principle of anti-invasion and anti-disease 
responses by blocking the invasion of erythrocytes by merozoites and prevent-
ing malarial disease [88]. The extensive genetic diversity of the parasite and the 
selective pressure are factors to be considered in the development of effective 
blood-stage vaccines. At present, several blood-stage antigens are in clinical trials: 
apical membrane antigen 1 (AMA1) [89], erythrocyte-binding antigen-175 (EBA-
175) [90], glutamate-rich protein (GLURP) [91, 92], merozoite surface protein 
(MSP) 1 [93], MSP2 [94], MSP3 [95–97] and serine repeat antigen 5 (SERA5) 
[98]. All these antigens are highly expressed on the surface of merozoites. During 
the blood-stage vaccine development various assay such as ELISA, western blot 
and immunofluorescence assay, invasion inhibitory assay, antibody-dependent 
cellular inhibition (ADCI) assay, phagocytosis/opsonization assay, T cell-based 
assay and other antibody-based assays are in use for their screening of the candi-
date vaccine [99].
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3.3 Transmission-blocking vaccines
Transmission-blocking vaccines (TBV) target antigens on gametes, zygotes and 
ookinetes to prevent parasite development in the mosquito midgut [88, 100]. The 
aim of these vaccines is to induce antibodies against the sexual-stage antigens to 
block the ookinete-to-oocyst transition to stop the subsequent generation of infec-
tious sporozoites thereby acting as important tools for protection against epidemics 
[101, 102]. The leading vaccine candidates in this group include the P. falciparum 
ookinete surface antigens Pfs25 and Pfs28 and their P. vivax homologs Pvs25 and 
Pvs28. To improve the immunogenicity, Pfs25 was expressed as a recombinant 
protein that was chemically cross-linked to Exoprotein A and delivered as nanopar-
ticles [103]. This enhanced the immunogenicity of the vaccine in mice, and it is cur-
rently undergoing Phase I trials in humans. Because the antigens are never naturally 
presented to the human immune system, one of the potential limitations of the 
TBV approach is that the absence of natural boosting following immunization 
might limit efficacy [88]. The vaccine would confer no protection to the vaccinated 
individual unless combined with an effective pre-erythrocytic or erythrocytic 
vaccine. Nevertheless, TBVs could be important tools for a malaria elimination and 
eradication program, for prevention of transmission of the disease [88].
3.4 Novel usages of radiation attenuated sporozoites (RAS) and effects on the 
host immunity
A recent landmark finding that set the standards for immunological protec-
tion against malaria infection was established by immunization with irradiated 
sporozoites [82, 104]. Because the parasite undergoes morphological changes and 
displays antigenic variation at each stage of infection, whole parasite vaccines have 
an advantage [105–107]. In the early 1940s, Russell and Mohan [104] first demon-
strated that inactivated P. gallinaceum SPZs provided protection against challenge 
with infectious P. gallinaceum. In 1967, Nussenzweig et al. [82] reported that a 
killed P. berghei sporozoites (SPZs) vaccine was unsuccessful, but that an X-ray 
irradiated SPZ vaccine provided significant protection in an SPZ-challenge mouse 
model.
In the 1970s, researchers showed that immunizing human volunteers with 
bites from irradiated mosquitoes carrying P. falciparum SPZS (PfSPZ) or P. vivax 
SPZ (PvSPZs) provided protection against challenges with infectious SPZ 
[108–112]. Because infected mosquitoes cannot be used for immunizing large 
numbers of individuals, a team at the Vaccine Research Center, NIH developed 
an injectable and cryo-preserved irradiated PfSPZ vaccine that met the vaccine 
regulatory standards [58, 113]. The group succeeded in raising mosquitoes on 
an industrial scale to good manufacturing practice (GMP) levels and harvested 
large amounts of PfSPZ from the mosquito salivary glands. Although studies 
provided proof of concept that sporozoites could induce high-level immunity, 
as a vaccine for human use, PfRAS immunization was deemed impractical for 
many decades due to the complexity of administering a vaccine through natural 
way of mosquito bite, the requirement for a secure vivarium and a laboratory 
for maintaining P. falciparum in culture, and the perceived need for five or more 
immunization sessions to achieve a sufficient number of bites. Recently, it has 
been demonstrated that the Sanaria PfSPZ vaccine is safe, well tolerated, easily 
administered by syringe using a variety of routes, and can induce 100% protective 
efficacy against controlled human malaria infection (CHMI) when administered 
 intravenously [109, 114].
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The sterile immunity induced by RAS appears to be mediated primarily by 
CD8+ and CD4+ T cell-dependent mechanisms targeting antigens expressed by 
sporozoites and liver-stage parasites [115–118]. Antibodies also appear to contribute 
to protection. Studies in mice and humans show that immunization with RAS 
induces sporozoite-neutralizing antibodies that recognize the CSP, an abundant 
protein forming the surface coat of the sporozoites [109, 119, 120]. This finding 
led to the cloning of P. falciparum CSP and the formulation of several CSP-based 
sub-unit vaccines designed to induce protective antibodies [121, 122]. Although 
efficacy was low, subsequent development of CSP using a particle-based approach 
has led to the currently most advanced malaria sub-unit vaccine, RTS, S/AS01, 
that elicits 30% protection in young children [123] primarily mediated by anti-CSP 
antibodies and CD4+ T cells [124, 125]. The partial efficacy of these first generation 
subunit vaccines suggests that a better understanding of RAS-induced protective 
mechanisms may provide a rationale to develop alternative or improved subunit 
strategies using newly discovered antigens or more potently inducing cell-mediated 
immunity. Despite all difficulties, the most convincing evidence that vaccination 
against malaria is feasible has come from experimental studies in rodents, monkeys 
and human subjects in which attenuated sporozoites induced sterile protective 
immunity.
3.5 Current status and future development: role of radiation in malaria vaccine 
development
The first whole sporozoites vaccine (WSV) studied in both rodents and 
humans were RAS and also the first to confer protection in humans when 
administered by mosquito bites. A major advance for vaccine development was 
the ability to isolate a purified, aseptic, and cryo-preserved product of RAS for 
clinical trials (PfSPZ vaccine). A subsequent scientific advance showed that 
intravenous (IV) administration of PfSPZ vaccine was required for inducing 
potent immunity in humans [109]. These studies provided the first evidence for 
using IV administration of a preventive vaccine in humans. More recent results 
with PfSPZ vaccine from sub-Saharan Africa reported that PfSPZ vaccine was 
well tolerated, safe, and easy to administer by direct venous inoculation (DVI) 
of healthy volunteers in the clinical trial setting. The proportion of participants 
with any infection from 28 days after the fifth vaccination to the end of the 
malaria season (20 weeks) was lower in the vaccinated group than in the control 
group [126]. These data suggest that WSV can provide some protection against 
malaria infection during intense transmission (93% infection rate among pla-
cebos) [79]. Recent progress in manufacturing whole organism vaccines has 
prompted several vaccinology questions: (1) Can whole sporozoite vaccines be 
improved? (2) What are the optimal doses, routes of administration, and adju-
vants that confer sterilizing immunity? (3) Can other antigens be included? (4) 
Are we exploring all protective immune mechanisms? (5) Does efficacy differ in 
populations from endemic versus non-endemic areas? (6) What is the impact of 
antigen polymorphisms? [80].
The future lies in improving dosing strategy, immunogenicity enhancement, and/
or alternative vaccine approach for populations in malaria-endemic regions. To halt 
the spreading of the malaria infection is not only the development of the vaccine 
against it, however; the mosquito biology equally holds the importance in understand-
ing the malaria pathophysiology and parasite biology which may be understand more 
in detailed by radiation biology [127]. Combination of different approaches based on 
attenuated whole organism sporozoites may be a valuable tool that would help unearth 
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host mechanisms of protection as well as surrogate measures of immune protection for 
malaria, thus providing crucial leads towards discovery of long-awaited vaccine [128].
4. Conclusion
Malaria is one of the most fatal diseases in the world related to humans in 
terms of morbidity and mortality. The asexual blood stage P. falciparum culture 
in vitro was successfully achieved in the early 1980s. However, various aspects 
related to their life cycle are unclear. The technological advancements in the 
field of epidemiology and entomology supported the research not only in 
reducing the burden but also allow scientists to go one step further in malaria 
parasitology by the staining the different stages of the parasites. The reports of 
the emergence of drug resistance in last decade against the various Plasmodia 
strains resulted in the serious condition to find out the causes. Given this bleak 
situation, the need to develop additional control measures, such as the malaria 
vaccine, is indeed. Understanding the mechanism of protective immunity to 
natural infection is critical in engineering an effective vaccine. The usage of 
radiation therapy in various medical fields has gained the attention of the malar-
ial biologist to make the next generation vaccines for the long-lasting immunity. 
Various approaches through whole sporozoites vaccines may prove to be the 
better vaccine candidates, however, the obstacles related to their manufacturing, 
formulation, and availability to mankind needs further experimental validation.
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